Category: Wall Street Beat
Inogen confirms its outlook for the rest of 2014 and issues its 2015 forecast, predicting revenue growth of 20% to 25% next year.
The number of initial public offerings for medical device companies jumped fourfold in 2014, according to a MassDevice.com analysis.
Click to enlarge
It was, as predicted, the year of the IPO for medical device companies, with 25 filing initial public offerings during 2014, according to a MassDevice.com analysis.
Symmetry Surgical is now officially independent of Symmetry Medical, as the surgical instrument company debuts on the NASDAQ exchange.
Here's a look at some of the top Wall Street stories for medical device companies this week: Will Stryker bid on Smith & Nephew this week?; Medtronic expects to free up to $4B after IRS beef is settled; Second Sight CEO Greenberg: Next-gen 'bionic eye' could treat nearly all forms of blindness; HCA hospitals halt use of uterine fibroid surgical tool
HCA Holdings halts the use of laparoscopic power morcellators in uterine fibroid surgeries in all 278 of its facilities, after the FDA raises the warning level on the cancer risk associated with the devices.
(Reuters) — HCA Holdings (NYSE:HCA), the largest for-profit U.S. hospital operator, said a procedure for removing uterine fibroids that's been linked to the spread of cancer will no longer be performed at its facilities.
Medtronic says it expects to repatriate as much as $4 billion in cash after it resolves a dispute with the IRS involving its Puerto Rico subsidiary.
Medtronic (NYSE:MDT) said today that it expects to land a substantial windfall once it resolves a dispute with the IRS over the next "couple of years."
Speculation mounts again about a possible Stryker offer for Smith & Nephew now that a 6-month no-bid period has ended.
UPDATED Nov. 24 with analysis from Morgan Stanley.